HUP0303355A2 - Stabil pergolid mezilát és eljárás előállítására - Google Patents

Stabil pergolid mezilát és eljárás előállítására

Info

Publication number
HUP0303355A2
HUP0303355A2 HU0303355A HUP0303355A HUP0303355A2 HU P0303355 A2 HUP0303355 A2 HU P0303355A2 HU 0303355 A HU0303355 A HU 0303355A HU P0303355 A HUP0303355 A HU P0303355A HU P0303355 A2 HUP0303355 A2 HU P0303355A2
Authority
HU
Hungary
Prior art keywords
pergolide mesylate
making same
stable
stable pergolide
mesylate
Prior art date
Application number
HU0303355A
Other languages
English (en)
Inventor
Minutza Leibovici
Ruth Tenengauzer
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of HUP0303355A2 publication Critical patent/HUP0303355A2/hu
Publication of HUP0303355A3 publication Critical patent/HUP0303355A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/02—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with hydrocarbon or substituted hydrocarbon radicals, attached in position 8

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

A találmány tárgya formulázás és eljárás olyan pergolid mezilátelőállítására, amelyből alapjában véve stabil pergolid mezilátot lehetelőállítani stabilizálószerek nélkül. Ó
HU0303355A 2000-08-08 2001-08-07 Stable pergolide mesylate and process for making same HUP0303355A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22377400P 2000-08-08 2000-08-08
PCT/US2001/024713 WO2002011727A1 (en) 2000-08-08 2001-08-07 Stable pergolide mesylate and process for making same

Publications (2)

Publication Number Publication Date
HUP0303355A2 true HUP0303355A2 (hu) 2004-01-28
HUP0303355A3 HUP0303355A3 (en) 2005-06-28

Family

ID=22837926

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0303355A HUP0303355A3 (en) 2000-08-08 2001-08-07 Stable pergolide mesylate and process for making same

Country Status (8)

Country Link
US (1) US6689384B2 (hu)
EP (1) EP1318813A4 (hu)
JP (1) JP2004505917A (hu)
AU (1) AU2001286418A1 (hu)
CA (1) CA2418915A1 (hu)
HU (1) HUP0303355A3 (hu)
IL (1) IL154290A0 (hu)
WO (1) WO2002011727A1 (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1318813A4 (en) 2000-08-08 2005-09-07 Teva Pharma STABLE PERGOLIDE MESYLATE AND PROCESS FOR MAKING SAME
AU2003215461A1 (en) * 2002-03-26 2003-10-08 Bernard Charles Sherman Stable tablets comprising pergolide mesylate
AR040682A1 (es) * 2002-07-25 2005-04-13 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
CN101849921A (zh) * 2004-08-13 2010-10-06 贝林格尔·英格海姆国际有限公司 包含普拉克索或其可药用盐的延长释放片剂
JP4971159B2 (ja) * 2004-08-13 2012-07-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング プラミペキソール又はその薬学的に許容しうる塩を含有する徐放性ペレット製剤、その製法及び使用
KR20070058540A (ko) * 2004-10-01 2007-06-08 니폰 조키 세야쿠 가부시키가이샤 고형 의약제제
TWM281293U (en) * 2005-05-06 2005-11-21 Harvatek Corp Optoelectronic chip array package structure
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
CA2641665A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Modified release formulation
US20080254118A1 (en) * 2007-04-11 2008-10-16 Hans-Werner Wernersbach Process for preparing pramipexole dihydrochloride tablets
US20080254117A1 (en) * 2007-04-10 2008-10-16 Noel Cotton Process for preparing pramipexole dihydrochloride tablets
US20190374534A1 (en) 2018-06-08 2019-12-12 Boehringer Ingelheim Vetmedica Gmbh Liquid pharmaceutical compositions comprising pergolide

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797405A (en) * 1987-10-26 1989-01-10 Eli Lilly And Company Stabilized pergolide compositions
US5114948A (en) * 1989-10-19 1992-05-19 Eli Lilly And Company Stabilized pergolide compositions
FR2680106B1 (fr) * 1991-08-09 1994-03-11 Corbiere Gerome Procede de realisation de formes pharmaceutiques stables d'un derive d'ergoline et les compositions pharmaceutiques ainsi obtenues.
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
EP1318813A4 (en) 2000-08-08 2005-09-07 Teva Pharma STABLE PERGOLIDE MESYLATE AND PROCESS FOR MAKING SAME

Also Published As

Publication number Publication date
JP2004505917A (ja) 2004-02-26
CA2418915A1 (en) 2002-02-14
AU2001286418A1 (en) 2002-02-18
EP1318813A4 (en) 2005-09-07
EP1318813A1 (en) 2003-06-18
WO2002011727A1 (en) 2002-02-14
US6689384B2 (en) 2004-02-10
HUP0303355A3 (en) 2005-06-28
IL154290A0 (en) 2003-09-17
US20020054904A1 (en) 2002-05-09

Similar Documents

Publication Publication Date Title
HUP0400149A2 (hu) Új fertőtlenítőszerek
HUP0402029A2 (hu) Peptidalapú multimer célzott kontrasztanyagok
HUP0303355A2 (hu) Stabil pergolid mezilát és eljárás előállítására
HUP0303996A2 (hu) Vakcinakészítmények
MXPA02012795A (es) Carvedilol.
HUP0400442A2 (hu) Kémiailag módosított inzulin pulmonáris beadása és eljárás az előállítására
NO20042816L (no) Fremgangsmater for maling av kraften av glatirameracetat
IS2170B (is) Sýklópentanóindól, efnablöndur sem innihalda slíkefnasambönd og meðhöndlunaraðferðir
LU91710I9 (hu)
DE60009511D1 (de) Nematizide trifluorbutene
HUP0302874A2 (hu) Eljárás risperidon előállítására
NO20054763L (no) Salter av clopidogrel og fremgangsmate for fremstilling derav
HUP0300755A2 (hu) Heparinszármazék poliszacharid keverékek, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0204010A2 (hu) Új szertralin-hidroklorid polimorfok, eljárás az előállításukra, az új polimorfokat tartalmazó gyógyszerkészítmények és alkalmazásuk
PL371127A1 (en) 6-aminomorphinane derivatives, method for the production and use thereof
DE50305587D1 (en) 2-heteroarylcarbonsäureamide
HUP0303144A2 (hu) Eljárások szubsztituált 2-(2-piridil-metil)-szulfinil-1H-benzimidazolok előállítására
HUP0300972A2 (hu) Gatifloxacin-pentahidrát
HUP0401092A2 (hu) 6-Fenil-7-[(fluor-alkil)-amino]-5-halogén-triazolopirimidinek mint fungicidek, előállításuk és alkalmazásuk
NO20033318D0 (no) 2H-1-benzopyranderivater, fremgangsmåte ved fremstilling samt farmasöytiskesammensetninger derav
TR200402030T4 (tr) İkame edilen I-aminobutan-3-ol-türevleri
NO20031413D0 (no) Ny fremgangsmåte for fremstilling av oksabispidiner
HUP0203740A2 (en) Food product and process
AR028316A1 (es) Gen de masa nsea elevada del cromosoma 11q13.3
WO2001049651A3 (de) Aminomethyl-phenyl-cyclohexanonderivate

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees